Characteristics of Ectopic Adrenocorticotropic Hormone Syndrome Due to Thymic Carcinoid and Analysis of the Molecular Mechanism
Bi Yu-Fang,Ye Lei,Chen Yu-Hong,Ning Guang,Sun Shou-Yue,Jiang Lei,Zhu Na,Zhou Wei-Wei,Wang Wei-Qing
DOI: https://doi.org/10.1097/00029330-200804010-00018
2008-01-01
Abstract:Ectopic adrenocorticotropic hormone (ACTH) secretion from a non-pituitary tumor is a main cause of Cushing's syndrome, which is associated with significant morbidity and mortality. Although early studies showed that the predominant cause of ectopic Cushing's syndrome is small cell carcinomas of the lungs, the incidence of carcinoid, including thymic carcinoid, has increased substantially in recent surveys.1 This evidence suggested that the clinical syndrome of ectopic ACTH production only occurs in tumors with high proopiomelanocortin (POMC, the precursor to ACTH) transcripts generated from the start of the pituitary transcription initiation site.2 Recently a series of transcription factors that participate both in the differentiation and in POMC gene expression in mature pituitary corticotroph cells3 have been identified, but the molecular mechanism for ectopic POMC overexpression remains obscure. We report here a case of Cushing's syndrome caused by an ACTH-producing thymic carcinoid. We analyzed the expression of several corticotroph-associated transcription factors in the tumor tissue to reveal a possible underlying molecular mechanism. CASE REPORT A 44-year-old man presented with significant weight gain, weakness and a psychiatric symptom. A physical examination showed pigmentation, moon-like face, central obesity, and edema in the eyelids and lower extremities. The patient's blood pressure was elevated to a systolic blood pressure of 160-180 mmHg and a diastolic blood pressure of 100-110 mmHg. The laboratory studies indicated severe hypokalemia (serum potassium 1.97 mmol/L, normal range 3.5-5.1 mmol/L) and hyperglycemia (fasting blood glucose 11.07 mmol/L, normal range 3.9-6.1 mmol/L). The thyroid function tests revealed hypothyroidism with TT3 0.6 nmol/L (normal range 0.89-2.44 nmol/L), TT4 56.9 nmol/L (normal range 62.67-150.84 nmol/L), FT3 1.09 pmol/L (normal range 2.62-6.49 pmol/L), FT4 7.35 pmol/L (normal range 9.01-19.04 pmol/L) and TSH 0.3 μIU/ml (normal range 0.1-10.0 μIU/ml). The basal serum cortisol level was 41.8 μg/dl (normal range 7-22 μg/dl) at 8:00 a.m., and the circadian rhythm disappeared with 25.9 μg/dl and 43.8 μg/dl at 4:00 p.m. and 12:00 p.m. respectively (serum samples were collected in one day). The levels of plasma ACTH (536.3-625.0 pg/ml, normal range 12-78 pg/ml) and the 24 hours urine free cortisol (UFC, 3859 μg/24 h, normal range 20-90 μg/24 h) were markedly raised. After the administration of 2 mg and 8 mg dexamethasone, the 24 hours UFC changed to 3260 μg/24 h and 2972 μg/24 h respectively. These negative suppression results combined with pigmentation, edema and hypokalemia suggested that endogenous hypercortisolism is sustained by an ACTH-secreting non-pituitary tumor. The magnetic resonance imaging (MRI) revealed normal pituitary and the abdominal computed tomography scan showed bilateral adrenal hypertrophy. A chest X-ray and a computed tomography imaging detected a mediastinal mass measuring more than 10 cm in diameter (Figure 1).Figure 1.: X-ray chest film (A) and chest computed tomography scan (B) showed a mass in the middle and inferior mediastinum.The patient underwent a median sternotomy and a resection of the mediastinal mass. The resected tumor measured 14 cm × 9.0 cm × 6.0 cm. After the procedures, the serum potassium, fasting blood glucose, and cortisol level immediately fell within the normal ranges (Table 1). The plasma ACTH level decreased gradually after the resection; it was below the upper limit of the normal range 3 hours after surgery and decreased to 25 pg/ml on the third day (Figure 2). The clinical symptoms, including skin pigmentation, were significantly improved after surgery.Table 1: Hormonal measurement before and after surgeryFigure 2.: ACTH level was showed at a series of time after surgery. Dramatic decline was observed immediately after the resection of the tumor, and 3 hours later the ACTH level was normal. Since then the level further decreased to 25 pg/ml on the third day. ACTH: adrenocorticotropic hormone.A histological examination revealed round and polygonal cells with cytoplasmic lucent granules and increased vascularity, which are consistent with thymic carcinoid. Infiltration of the peripheral vessels and adipocyte tissue was detected. The immunohistochemistry test stained positive for ACTH (Figure 3).Figure 3. A:: Histological examination revealed thymic carcinoid (HE stain, original magnification ×200). B: Arrow indicated strong positive ACTH staining. ACTH: adrenocorticotropic hormone.The patient has been followed up for 6 years since the treatments and remains in good health. RT-PCR analysis of corticotroph-associated genes expression To further investigate how a tumor cell outside pituitary acquired the ability to produce ACTH, we analyzed the expression of several corticotroph-associated transcription factors in the thymic carcinoid tissue. RNA extraction and RT-PCR procedures were previously described.4 The primers are listed in Table 2. As expected, a strong RT-PCR signal was detected for the POMC gene in the tumor tissue. The T-box binding factor, Tpit gene and the NeuroD1 gene were also overexpressed (Figure 4).Table 2: The primers of POMC, Tpit and NeuroD1 geneFigure 4.: RT-PCR analysis of the expression of the corticotroph-associated transcription factors. TC: thymic carcinoid. NT: normal thymus. POMC: proopiomelanocortin.DISCUSSION Thymic carcinoids are classified as neuroendocrine carcinomas, ranging from well-differentiated neuroendocrine carcinomas (carcinoids) to small cell carcinomas and accounting for approximately 2% to 4% of all anterior mediastinal tumors. Thymic carcinoids may be associated with ectopic ACTH syndrome (EAS) or form a part of the multiple endocrine neoplasms type 1 syndrome.5 Since year 2000, we have diagnosed 17 cases of EAS, 8 of which have been identified with localization including 6 cases of thymic carcinoid.6 The patient reported here was the most typical case. The neuroendocrine thymic tumors associated with EAS may occur at any age from 4 to 64 years, mostly between 20 and 40 years and as frequently in men as in women. The patients may present typical physical signs of hypercortisolism or primary metabolic disorders. The cushingoids are sometimes indistinguishable from Cushing's disease, but skin pigmentation, hypertension, edema, severe hypokalemic with myoasthenia are more predominant in EAS than in Cushing's disease.7 The patient here developed severe weakness caused by hypokalemia, visible pigmentation and edema in the eyelids and lower extremities. These features were shortly and significantly relieved after the resection of the tumor. Hypothyroidism can be sometimes indicated by the inhibition of the redundant adrenal cortical hormone's secretion of thyrotrophin-releasing hormone (TRH) and thyrotropic-stimulating hormone (TSH). The manifestation of Cushing's syndrome, hypercortisolism with negative results from the 2 mg dexamethasone suppression test, elevated ACTH levels, and bilateral adrenal hyperplasia suggested a pituitary adenoma or an ectopic secretion of ACTH. The establishment of the EAS diagnosis relies on the negative response to stimulating or inhibiting agents including the 8 mg dexamethasone, the corticotropin releasing hormone (CRH), or the metyrapone. However, EAS tumors may sometimes acquire more differentiation features of the pituitary cells; therefore none of these methods is accurate enough to definitively distinguish between pituitary or nonpituitary tumors. It has been indicated that when the inferior petrosal sinus and the peripheral vein samplings are combined with the CRH test, the results can reach an accuracy rating of 100%,8 but the possible false negative results and the potential risk of brain injury limit its application in clinical diagnosis.9 According to our own data, we recommend the 8 mg dexamethasone test for its convenience and accuracy. Among the 17 cases of EAS we have diagnosed, all 17 had negative suppression results including this case. Localization is another challenge for an endocrinologist because some ectopic ACTH-secreting tumors can be exceedingly small and may not be depicted on various imaging tests even after a long-term follow-up. However, if an ectopic source is highly suspected, a chest X-ray and a CT are strongly recommended especially for the follow-up of those with occult tumors. It should be emphasized that thymic remnant tissue and small thymic carcinoid tumours might have a similar appearance on the CT scan and will be potentially misleading, resulting in an incorrect diagnosis and unnecessary thoracotomy.10 Since thymic tissue regresses with age, this concern will be generally excluded in patients above 40.10 Positron emission tomography (PET) and octreotide radio-labeled scans may also be useful in the localization but no privileges were found in our survey.11 Once the tumor is clearly detected, resection is the best choice for the removal of the neuroendocrine tumor of the thymus. Thymic carcinoid tumors tend to undergo a progressive malignant transformation and metastasis into either a lymph node, or change haematogenously into other organs. Therefore an aggressive local resection such as median sternotomy is recommended for most cases. Despite the aggressiveness of the treatment, thymic carcinoid tumors have a poor prognosis with a ten-year survival rate less than 50% with the lowest survival rate of 35%.12 Local infiltration was demonstrated in this described case. The patient has been followed up for more than 6 years, and he still remains in good health. Physiologically, ACTH results primarily from a pituitary transcript of a POMC gene in the corticotroph cell. The POMC precursor molecule is cleaved by prohormone convertase 1 into ACTH. We detected the overexpression of the POMC gene in the thymic carcinoid tissue. However, due to the lack of in vitro cell models, why and how a POMC gene is expressed in an ACTH-producing carcinoid tissue remains obscure. We wonder whether the transcription factors acting on a POMC gene promoter are maintained not only in pituitary corticotroph tumors but also in a thymic carcinoid, which are both well differentiated and have slow proliferation. A RT-PCR study demonstrated that the Tpit and NeuroD1 expressions were specifically conserved in this carcinoid tissue, suggesting a possible role in ectopic POMC expression. NeuroD1 (BETA2) and Tpit are cell-specific activators of pituitary POMC gene transcription. The expression of both factors slightly precedes that of POMC at embryonic d 12.5 of a mouse's pituitary development.13 A gel-shift assay indicated that NeuroD1 was absent from the DMS-79 cell, a small cell lung carcinoma (SCLC) cell line as an in vitro model to study the ectopic ACTH syndrome.14 We found a sharp band of NeuroD1s in the carcinoid tissue, because carcinoids are better differentiated than SCLC tumors or because this particular mRNA cannot code for a bioactive protein. Messager et al15 also detected positive Tpit and NeuroD1 expression in bronchus carcinoids with positive ACTH staining. However, the conclusion of their exact roles in an ectopic POMC expression still needs further evidences. In conclusion, we have reported a case of EAS caused by thymic carcinoid. A specific RT-PCR test detected abnormal expression of POMC, Tpit, and NeuroD1 in the tumor tissue, suggesting that the mechanism of POMC transcription in a normal pituitary corticotroph may be partly reserved in the thymic carcinoid with EAS.